Crocus Laboratories Inc. is a private Canadian Biotech Company which is engaged in the design and synthesis of:
The team has extensive experience in drug discovery/medicinal chemistry - particularly in the areas of oncology, infectious diseases and ophthalmology.
Dr. Arkadii Vaisburg is the founder and President of Crocus Laboratories Inc. (Montreal, Canada) which started its operation in 2014. Prior to that, he was the Executive Director Medicinal Chemistry at MethylGene Inc. in Montreal (currently Mirati Therapeutics in San Diego). There he created the company’s kinase chemistry platform which resulted in the discovery of multi-kinase inhibitors Glesatinib (MGCD265) undergoing phase II clinical trials and Sitravatinib (MGCD516) currently in phase I clinical trials - both in Non-Small Cell Lung Cancer. He also contributed to the development of HDAC inhibitors Mocetinostat (MGCD0103, an anticancer agent) and MGCD290 (an antifungal agent) – both reached phase II clinical trials.
Dr. Vaisburg has over 20 years of drug discovery and development experience. He is co-author of 39 scientific publications and review articles in peer-reviewed journals and co-inventor of 38 patent applications.
Dr. Vaisburg received his Ph.D. degree in Organic Chemistry from N.D. Zelinsky Institute of Organic Chemistry, Russian Academy of Sciences in Moscow and completed his post-doctoral research at the University of Linz, Austria.
is seeking collaborations and partnerships with Academic Groups, Biotech
and Pharmaceutical Companies with the goal to discover and develop novel medicines.